Novo Nordisk Raises Forecasts on New Obesity Drug

The transcript discusses Novo Nordisk's strong business momentum, driven by growth in diabetes and obesity treatments. The company faces supply challenges but is ramping up manufacturing to meet demand. Despite supply chain issues, margins remain stable. Novo Nordisk is investing heavily in research and development, with a focus on innovation and clinical trials. The pandemic has impacted business, but the company is adapting and expects continued growth. Plans for global expansion, particularly in obesity medication, are underway.

What strategies are being implemented to address supply chain issues?

How does the speaker view the impact of COVID-19 variants on the company's outlook?

What expectations does the company have for the approval of their new diabetes medication in different markets?